Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Inclusion Criteria

• •\- 1.18 years and older, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, Life expectancy ≥ 6 months.
• •2\. Prostate cancer. 3. Serum testosterone \<50 ng/dL (or 1.7 nmol/L). 4. Prostate cancer progression or lesion metastasis. 5. Restriction of antiandrogen therapy. 6. Restriction of Radiation therapy. 7. The treatment period of ketoconazole for prostate cancer was not exceed 7 days.
• •8\. Has not used opioid analgesics and azole drugs within 4 weeks before the first dose.
• •9\. Question 3 of the Concise Pain Questionnaire (BPI-SF) scored from 0-3 points.
• •10\. Adequate laboratory indicators. 11. Must be able to swallow tablets. 12. No pregnant or breastfeeding women, and a negative pregnancy test. 13. Understood and signed an informed consent form.